
July 23, 2020
Excellent research results for CAR-T therapy against Hodgkin lymphoma
CAR-T immunotherapy has been used to treat Hodgkin lymphoma with remarkable success for the first time, according to the results of an early phase clinical trial.
July 23, 2020
CAR-T immunotherapy has been used to treat Hodgkin lymphoma with remarkable success for the first time, according to the results of an early phase clinical trial.
March 11, 2020
February 13, 2020
When traditional cancer treatment options failed, Sabrina Shelton's care team referred her to UNC for a CAR-T therapy clinical trial.
January 30, 2020
A discovery by University of North Carolina Lineberger Comprehensive Cancer Center researchers could allow scientists to fine-tune genetically engineered immune cells to heighten their killing power against tumors or to decrease their activity level in the case of severe side effects. In a study published in Cancer Cell, researchers led by UNC Lineberger’s Gianpietro Dotti, …
May 20, 2019
Jonathan Serody, MD, explains in a two-minute video the action behind chimeric antigen T-cell, or CAR-T, immunotherapy and how UNC Lineberger is designing, developing and delivering CAR-T therapies to treat cancers that fail to respond to standard treatments.
January 30, 2019
The multi-institutional team, which is co-led by UNC Lineberger's Gianpietro Dotti, MD, and includes six UNC Lineberger researchers, will focus on developing chimeric antigen receptor T-cell (CAR-T) therapies to recognize and attack T-cell lymphoma, a group of rare cancers of the blood and immune system.
December 20, 2018
At the 60th American Society of Hematology Annual Meeting in San Diego on Dec. 3, Eben Lichtman, MD, presented preliminary findings from preclinical studies of CAR T-cells directed towards a potential target called B7-H3, which is found on the cell surface of certain types of AML.
December 3, 2018
At the 60th American Society of Hematology Annual Meeting in San Diego on Monday, UNC Lineberger's Natalie Grover, MD, presented preliminary results from a clinical study of an investigational cellular immunotherapy for Hodgkin lymphoma and non-Hodgkin lymphoma expressing the CD30 protein marker.
February 28, 2018
A team led by UNC Lineberger's Gianpietro Dotti, MD, has engineered immune cells to hunt glioblastoma, the most lethal primary brain tumor. They presented their findings in Science Translational Medicine.
April 10, 2017
Seeking to help in the development of treatments for metastatic cancer, Alice Lehman of Charlotte has donated $4 million to further the work of UNC Lineberger's new cellular immunotherapy research program.